Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2003

View Archived Issues

Integrated pharmacokinetic/pharmacodynamic model developed for SB-480848

Garenoxacin pharmacokinetics similar in healthy and hepatically impaired subjects

Pharmacokinetics, metabolism and excretion of single-dose sitafloxacin in healthy males

Food intake does not alter the pharmacokinetics of multiple-dose lonafarnib

No pharmacokinetic interactions for memantine and donepezil in healthy volunteers

DOV reacquires diltiazem rights from Biovail

Results of argatroban and gpIIb/IIIa inhibitor combination study

Isis outlines 2003/4 milestones

New patent broadens protection for Virulizin

Sumitomo presents new muscarinic M3 antagonists for use in urinary incontinence

Novel PARP inhibitors in early development at Icos

JT researchers prepare and test new HIV integrase inhibitors

New antitumor duocarmycin analogues covered by Medarex patent

Novel sodium channel blockers for pain, seizures and other disorders

E.U. approval for NeoRecormon use once every two weeks for renal anemia

Metvix PDT approved in Australia

Remicade approved for long-term use in fistulizing Crohn's disease

Biosyn acquires rights to HIV microbicide candidate from NIH

AP-5346 enters phase I trials in Europe

Brand name announced for decitabine

Graffinity enters research collaboration with Serono

Ongoing program for clopidogrel in atherosclerosis

HYB-2055 enters the clinic

Water-soluble taxoids for use in tumor-activated prodrugs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...